This trial is testing nivolumab in combination with carboplatin and paclitaxel versus the usual treatment of carboplatin and paclitaxel for anal cancer that has spread to other parts of the body.
1 Primary · 3 Secondary · Reporting Duration: Up to 2 years
205 Total Participants · 2 Treatment Groups
Primary Treatment: Paclitaxel · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Kaiser Permanente-San Francisco||100.0%|
|Did not meet criteria||50.0%|